A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Recruiting · Phase 3 · NCT04715646
Conditions: Epilepsy
At a glance
- Research payments reported, 2025
- $19,443
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Brivaracetam (drug)
- Dates
- Started 2021-03-11; completion 2030-07-08
- Results posted
- Not yet
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
From ClinicalTrials.gov, last updated 2026-07-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $19,443 in research payments for this study in 2025 (1 payments).
Products named: Briviact
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Health Services $19,443
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.